SAN DIEGO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced that a deadline is coming up on February 28th in the lawsuit that was filed for certain investors in shares of Instadose Pharma Corp. (OTC: INSD).
Investors who purchased in excess of $150,000 in shares of Instadose Pharma Corp. (OTC: INSD) have certain options and there are short and strict deadlines running. Deadline: February 28, 2022. Those OTC: INSD investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
A lawsuit was filed against Instadose Pharma Corp. over alleged Securities Laws violations. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that Instadose had performed inadequate due diligence into the Business Combination and/or ignored significant red flags associated with Instadose Canada, that Instadose's internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company, that the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Instadose Pharma Corp. (OTC: INSD) should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
